Clinical Trials Browser

INDUSTRY × ixazomib × 90 days × Clear all

NCT02343042 2026-05-04

STOMP

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4 Terminated

Multiple Myeloma